Antitumor effect of salidroside on mice bearing HepA hepatocellular carcinoma by Song, Hanjun et al.
1961
KEY WORDS: apoptosis, hepatocellular carcinoma, salidroside.
* Author to whom correspondence should be addressed. E-mail: jmsdxjianjie@163.com
Latin American Journal of Pharmacy
(formerly Acta Farmacéutica Bonaerense)
Lat. Am. J. Pharm. 34 (10): 1961-7 (2015)
Regular article
Received: May 21, 2015
Revised version: August 4, 2015
Accepted: August 5, 2015
Antitumor Effect of Salidroside on Mice
Bearing HepA Hepatocellular Carcinoma
Hanjun SONG 1, Jianjie WANG 1 *, Molin WANG 1, Hang DONG 2,
Lijiang LI 2, Tengyuan ZHANG 1 & Shaobo ZHOU 3
1 College of Basic Medicine, Jiamusi University, No. 148 Xuefu Street, Jiamusi 154007, P.R. China
2 The First Affiliated Hospital, Jiamusi University, No. 348 Dexiang Street, Jiamusi 154002, P.R. China
3 Department of Life Science, Institute of Biomedical and Environmental Science and Technology,
University of Bedfordshire, Luton, LU1 3JU, UK
SUMMARY. Salidroside, a phenylpropanoid glycoside extracted from Rhodiola rosea L., has antiprolifera-
tive effects on tumour cells in mice. However it’s antitumor mechanism remains largely unknown. In this
study, 4 groups of mice bearing hepatocarcinoma cells were given treatment with vehicle alone, cyclophos-
phamide (25 mg/kg, i.p.) and salidroside, either 100 or 200 mg/kg (p.o.) for 14 days. The morphology of tu-
mour specimens was analysed by transmission electron microscopy. Apoptotic cells in sections of mouse
tumour tissue were analysed using an in situ apoptosis kit. The expression of Bcl-2, Bax and caspase 3 mR-
NA were examined with RT-PCR. The results showed that the tumour weights in groups 100 or 200
mg/kg/day of salidroside were reduced significantly (45.34 and 52.48% respectively), compared to vehicle
groups. Salidroside increased apoptotic cells index, e.g. in 200 mg/kg group, it was four times higher com-
pared to the control group. Even more, treatment with salidroside decreased Bcl-2 mRNA expression and
increased Bax and caspase 3 mRNA expressions. These indicated that the antitumor mechanism of
salidroside may induce tumour cell apoptosis in mice by triggering the mitochondrial-dependent pathway
and activation of caspase 3.
RESUMEN. Salidrósido, un glucósido fenilpropanoide extraído de Rhodiola rosea L., tiene efectos antiprolifera-
tivos sobre células tumorales en ratones. Sin embargo, el mecanismo antitumoral sigue siendo en gran parte des-
conocido. En este estudio, a 4 grupos de ratones portadores de células de hepatocarcinoma se les dio tratamiento
con vehículo solo, ciclofosfamida (25 mg/kg, i.p.) y salidrósido, ya sea 100 o 200 mg/kg (p.o.) durante 14 días.
La morfología de las muestras de células tumorales se analizó por microscopía electrónica de transmisión. Las
células apoptóticas en secciones de tejido de tumor de ratón se analizaron usando un kit de apoptosis in situ. La
expresión de mRNA de Bcl-2, Bax y caspasa 3 fueron examinados con RT-PCR. Los resultados mostraron que
los pesos de los tumores en los grupos de 100 o 200 mg/kg/día de salidrósido se redujeron significativamente
(45,34 y 52,48%, respectivamente), en comparación con los grupos de vehículos. El salidrósido aumentó el índi-
ce de células apoptóticas, por ej., en el grupo 200 mg/kg fue cuatro veces mayor en comparación con el grupo
control. Aún más, el tratamiento con salidrósido disminuyó la expresión de mRNA de Bcl-2 y aumentó las ex-
presiones de ARNm de Bax y caspasa 3. Estos resultados sugieren que el mecanismo antitumoral de salidrósido
puede inducir apoptosis de células tumorales en ratones mediante la activación de la vía mitocondrial dependien-
te y la activación de la caspasa 3. 
INTRODUCTION 
Hepatocellular carcinoma is the second and
third most common cause of cancer death in
males and females, respectively 1,2. The progno-
sis of these patients is poor because there is no
effective treatment 3,4. Although the therapeutic
methods for hepatocellular carcinoma have
made great progress, more than 80% of cases at
advanced stage are inoperable. Moreover, de-
spite patients having had surgery at an early
stage, the incidence of recurrence is approxi-
mately 20-25% in year one after operation 5-7.
Therefore, it is important to invest new drugs
for its effective treatment. 
Natural herbal plants have been demonstrat-
ed to be reliable and are potential sources used
to treat cancers. Many Chinese herbal medicines
have shown to be effective in cancer chemopre-
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vention and chemotherapy, with none or few
side effects 8. Salidroside [2-(4-hydroxyphenyl)
ethyl-β -D-glucopyranoside], is a phenyl-
propanoid glycoside and it is extracted from the
plant Rhodiola rosea L. (Fig 1). Some reports
have shown that salidroside has various phar-
macological effects including antioxidant, antifa-
tigue, anti-inflammation and immune enhance-
ment 9-11, as well as antitumor effects, e.g. in-
hibiting the proliferation of cervical cancer,
leukaemia cells K562, melanoma cloudman S91,
lung cancer cells A549, breast cancer, stomach
and liver cancer 12-16. Our previous study
showed that salidroside (100 and 200 mg/kg) in-
hibited the proliferation of tumour cells in hepa-
tocellular (HepA) mice and promoted the activi-
ties of cytotoxic T lymphocyte and natural killer
cells with no side effects 17. However, the antitu-
mor mechanism of salidroside remains largely un-
known. Therefore, this present study investigates
this by using a HepA bearing mouse model. 
MATERIALS AND METHODS
Chemicals and cell line
Salidroside was obtained from Shenyang
Pharmaceutical University (Shenyang, China).
Cyclophosphamide (CTX) was purchased from
HengRui pharmacy Inc. (Jiangsu province, Chi-
na). The terminal deoxyribonucleotide trans-
ferase-mediated nick-end labeling assays
(TUNEL) kit was purchased from KeyGEN Bio
(Nanjing, China). Trizol was purchased from
Gibco (Gaithersburg, MD, USA). Reverse tran-
scriptase cDNA synthesis kit was purchased
from Takara Bio (Dalian, China). The HepA
Hepatocellular cell line was obtained from Can-
cer Institute of Chinese Academy of Medical Sci-
ences (Beijing, China). All other chemicals used
were analytical reagent grade.
Experimental animals
Forty female Kunming mice aging 6-8 weeks
Figure 1. The structure of salidroside.
old (20.0 ± 2.0 g), were provided by the Experi-
mental Animal Center of Dalian Medical Univer-
sity. They were maintained under standard envi-
ronment conditions and fed with a standard pel-
let diet and free access to water. All animal ex-
periments were conducted in accordance with
the NIH Guide for the care and Use of Laborato-
ry Animals (NIH Publication No.80-23; revised
1978 and the number approved by Administrat-
ed-Committee of Laboratory Animals was
062310).
Animal model and treatment with drugs
The HepA hepatocellular cell line (107
cell/mL) was injected into the mouse peritoneal
in 10 mice (0.2 mL/mouse). After 7-10 days, as-
cites produced were drawn from HepA mice un-
der aseptic conditions, and they were diluted to
the concentration of 107 cells/mL in saline.
HepA cells (0.2 mL) were subcutaneously inject-
ed into the left limb axilla. After 24 h of inocula-
tion, mice were weighed and randomly divided
into four groups (n = 10). The group was ad-
ministered with vehicle alone (normal saline,
p.o.), and is the control group. The other group
was treated with cyclophosphamide (CTX,
25mg/kg, i.p., CTX group), which is considered
as the standard antitumor reference drug. The
other two groups were administered with
salidroside (either 100 or 200 mg/kg, p.o., re-
spectively). After 14 days 6,17, all mice were
weighed and killed, and the transplanted tu-
mours in four groups were removed and
weighed. According to the mean weight of the
tumour, the rate of tumour inhibition was calcu-
lated in the following method: the rate of inhibi-
tion (%) = (mean tumour weight of control
group - mean tumour weight of treated group)
/mean tumour weight of control group × 100 %.
Histology analysis
Tumour specimens were fixed in 10% (v/v)
neutral formalin solution for 24 h and processed
routinely by embedding in paraffin. Tissue serial
sections (4 µm) were stained with haematoxylin
and eosin (H&E staining) and examined under a
light microscope.
Morphology analysis by transmission
electron microscopy
Tumour specimens (1 mm3) were pre-fixed
with 2.5% glutaraldehyde in 0.1 mol/l phosphate
buffer at 4 °C for 2 h, and then rinsed thorough-
ly in phosphate buffer and post fixed in 1%
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OsO4 at 4 °C for 30 min. After being fixed, spec-
imens were dehydrated through a graded
ethanol series, and embedded in Epon (Epoxy
resin, Spi supplies, West chester, USA). The ul-
trastructure of cells were analysed in ultrathin
sections (70 nm) in a TEM (Hitachi H-800,
Tokyo, Japan). After, the sections were stained
with uranyl acetate and lead citrate 6.
TUNEL assay
Apoptotic cells in sections of mouse tumour
tissue from the four groups were detected by
using an in situ apoptosis detection kit accord-
ing to the manufacturer’s instructions. The dis-
tinctly brown staining of cells represents apop-
totic cells while the blue staining of cells shows
non-apoptotic cells under a light microscope.
The average number of positive cells was count-
ed in five randomly selected optical fields (200
tumour cells/per field). The apoptotic index (%)
was calculated as: (number of apoptotic cells /
total number of cells) × 100%.
RNA extraction and reverse transcription
polymerase chain reaction (RT-PCR)
Total RNA in tumour tissues was extracted
using Trizol reagent (Invitrogen). RT-PCR was
performed using reverse transcriptase cDNA
synthesis kit according to the manufacturer’s
protocol. One microgram of total RNA was re-
verse transcribed into cDNA and then followed
by PCR amplification using specific primers: Bcl-
2, forward: (5’-CCTGGCACCTGGCGG ATAGC-
3’) and reverse: (5’-CGACTGAAGAGTGAGC-
CCAGCAGAAC-3’); Bax, forward: (5’-GCTCT-
GAACAGATCATGAAGACAG-3’) and reverse:
(5’-CAATCCA AAGTGGACCTGAGG-3’); cas-
pase-3, forward: (5’-TTTGTTTGTGTGCTTCTG
AGCC-3’) and reverse: (5’-GATGTTCTGGAGA
GCCCCG-3’); β-actin, forward (5’-AATGGGTCA-
GAAGGACTCCTATGTGG-3’) and reverse: (5’-
CGCCTA GAAGCACTTGCGGTG-3’). Bcl-2 or
Bax was amplified by 30 cycles at 94 °C for 30
sec, 58 °C for 30 sec, and 72 °C for 40 sec in or-
der. Caspase 3 was amplified by 30 cycles at 94
°C for 45 sec, 52 °C for 45 sec, and 72 °C 1 min.
All procedures were followed by a 7 min exten-
sion at 72 °C. PCR products were elec-
trophoresed on a 1.0% agarose gel containing
ethidium bromide and visualized by ultraviolet-
induced fluorescence. The intensity of bands
was quantified by LabWork 3.0 UVP software
(UVP, USA).
Statistical analysis
All results were presented as mean ± stan-
dard deviation (S.D.). One-way analysis of vari-
ance and Duncan’s multiple range tests were
used to compare differences among the groups,
and P < 0.05 indicated a statistically significant
result.
RESULTS
Effects of Salidroside on tumour weight in
vivo
After daily administration of CTX (25 mg/kg,
i.p.) and salidroside (100 or 200 mg/kg, p.o.),
for two weeks, tumour weight was significantly
lower compared to the control group. The mean
tumour weight was 3.22 ± 0.67 g in the control
group, whereas it was 1.76 ± 0.45 and 1.53 ±
0.43 g in salidroside group (100 or 200 mg/kg
respectively), and was 1.47 ± 0.31 g in the CTX
group. The tumour inhibition rate was 45.34,
52.48, and 54.35 % in salidroside (100 or 200
mg/kg) and CTX group, respectively (Table 1).
Morphological changes of cell apoptosis
The morphological changes of cell apoptosis
were further studied in order to understand anti-
tumor mechanisms. Results in Fig. 2 showed
that in the control group, tumour cells of differ-
ent sizes and shapes were arranged closely. The
cells displayed a small cytoblastema and a larger
thickly stained nucleus and obvious heteromor-
phism and hyperplasia as well. However the
Body weight (g)
Groups n
Start End
Control 10 Vehicle 20.23 ± 2.02 21.79 ± 2.23 3.22 ± 0.67
CTX 10 25 21.48 ± 1.89 19.85 ± 1.34 1.47 ± 0.31* 54.35%
salidroside
10 100 20.69 ± 2.04 22.26 ± 2.85 1.76 ± 0.45* 45.34%
10 200 21.38 ± 1.91 23.17 ± 2.34 1.53 ± 0.43* 52.48%
Table 1. The inhibitory effect of salidroside on HepA solid tumours * p < 0.05 as compared with control group,
values are mean ± S.D.
Treatment
(mg/kg)
Inhibition
rate (%)
Mean weight
of tumour (g)
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number of tumour cells in the salidroside treat-
ment groups, especially in the high-dose group,
decreased markedly and tumour cell chromatin
accumulated at the side of the nucleic mem-
branes. The nucleic shape was irregular and the
surface of the nucleic membrane was rough.
The nucleus was broken but was encapsulated
by an intact membrane containing intact or-
ganelles and apoptotic bodies. TUNEL staining
results showed that the apoptotic index reached
23.32% in the salidroside group (Fig 4).
Tumour cell apoptosis in salidroside treated
groups was further confirmed by electron mi-
croscopy. Results in Fig. 3 show representative
pictures of apoptotic tumour cells in salidroside
treated groups that revealed cell shrinkage,
chromatin condensation, irregularly shaped cres-
cents at the nuclear edges, and fragmentation of
cells into membrane-wrapped apoptotic bodies. 
Expression of apoptosis-related genes in
tumour tissues
To further determine the mechanisms of
apoptosis induced by salidroside, the expression
of Bcl-2, Bax and caspase 3 mRNA were exam-
ined with RT-PCR. The results in Fig. 5 shows
Figure 3. Morphological changes of tumour cells in the HepA model treated with salidroside by electron mi-
croscopy. (A) The control group; (B) CTX group; (C) Salidroside group (200 mg/kg). Arrows reveal cell shrink-
age, chromatin condensation, irregularly shaped crescents at the nuclear edges, and fragmentation of cells into
membrane-wrapped apoptotic bodies. 
Figure 2. Morphological changes of tumours in the HepA model treated with salidroside (H&E staining
×400).(A) The control group. (B) CTX group. (C) Salidroside group (200 mg/kg). Arrows indicates the apoptotic
cells.
that compared to the control group, the expres-
sion of Bcl-2 mRNA decreased, while the ex-
pression of Bax and caspase 3 mRNA increased
in both salidroside treated groups. The down-
regulation of Bcl-2 mRNA and up-regulation of
Bax mRNA led to a decrease in the ratio of Bcl-
2/Bax. However, the expression of the above
apoptosis-related gene did not significantly
change in the CTX group.
DISCUSSION
This study further investigated into the effects
and mechanisms of salidroside on mice harbour-
ing HepA cells. The results demonstrated that
salidroside plays an important role in antitumor
activity. Compared with the control group,
salidroside administration can significantly de-
crease tumour weight, increase tumour inhibi-
tion rates, induce morphological changes indica-
tive of apoptosis, increase tumour cell apoptosis,
regulate Bcl-2 and Bax mRNA expressions, re-
ducing Bcl-2/Bax ratio, and increase caspase 3
activity. These findings are consistent with previ-
ous studies using salidroside, which induced cell
apoptosis and cell-cycle arrest in human breast
cancer cells and A549 lung cancer cells 15,16.
A B C
A B C
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Figure 4. Morphological and apoptotic index changes of tumour cells in the HepA model treated with salidro-
side (TUNEL staining ×200). (A) The control group. (B) CTX group (C) salidroside group (200 mg/kg). (D) The
changes of apoptotic index in the HepA cancer model in vivo treated with CTX and salidroside (100 and 200
mg/kg) for 14 days. * P < 0.05 vs. Control group.
Figure 5. Expression of apoptosis-related genes in tumour tissues. RT-PCR was performed to determine apopto-
sis-related mRNA expression. β-actin was used as a control. (B) The intensities of the Bcl-2 and Bax bands were
quantified and are shown as relative expression level after being normalized using β-actin. *P < 0.05, vs. control
group. (C) The ratio of Bcl-2 and Bax. (D) The intensity of caspase 3 was quantified and is shown as the rela-
tive expression level after being normalized by β-actin. *P < 0.05, vs. control group.
A
C
B
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Apoptosis, a physiological process in con-
trolling cell number and proliferation, helps
maintain homeostasis of multicellular organisms.
It is well recognized that an alteration in cellular
homeostasis occurs in cancer, disrupting the
balance between cellular proliferation and cell
death (apoptosis) 18,19. The imbalance of cell
proliferation and cell death might induce tu-
mour generation. Many anticancer drugs induce
tumour cell apoptosis, which is an obvious strat-
egy for cancer therapy 6,20. Traditional
chemotherapeutic drugs often kill tumour cells
by preventing mitosis and proliferation 8. Our
data suggest that salidroside can induce apopto-
sis of HepA cells in vivo, demonstrated by ob-
servations of cell shrinkage, chromatin conden-
sation, irregular nucleic shape, and the presence
of apoptotic bodies, under light microscopy and
electron microscopy. 
The mechanisms of apoptosis induced by
drugs are complex due to the differences in cell
types and drugs. The process is controlled by a
number of proteins. Among them, mitochondrial
and cell-surface death receptor-mediated apop-
tosis are the two principal pathways leading to
programmed cell death. The mitochondrial path-
way is thought to play a major role in response
to cancer treatment and is mediated by the Bcl-2
family proteins, which are consistently over-ex-
pressed in many tumour cells 21-23 and they act
as repressors of apoptosis by blocking the re-
lease of cytochrome-c, whereas proapoptotic
members, e.g., Bax, act as promoters 24. Their
effects are dependent on the balance between
antiapoptotic Bcl-2 and proapoptotic Bax 25,26.
Results in this present study showed that in the
salidroside group, the expression of Bcl-2 de-
creased and the expression of Bax increased.
The up-regulation of Bax expression and the re-
duction of Bcl-2 expression led to a decrease in
the ratio of Bcl-2/Bax, which may be responsi-
ble for the drug-induced apoptotic process.
Caspase 3 is an executioner caspase of the
apoptosis pathway 27. In the present study, after
administration with salidroside there was an in-
crease in caspase 3 mRNA, which indicated that
salidroside also promotes caspase 3 gene ex-
pression.
Therefore, the most likely explanation for
the antitumor mechanisms of salidroside is that
salidroside results in DNA damage of tumour
cells and that in response, a positive ratio be-
tween Bcl-2 and Bax leads to cytochrome c re-
lease from the mitochondria, which triggers the
mitochondrial-dependent pathway, finally lead-
ing to the activation of the caspase 3 and even-
tually to apoptosis.
CONCLUSION
In summary, salidroside results in the growth
inhibition of tumour cells by inducing apoptosis
in HepA tumour-bearing mice. The mechanism
is likely to occur through the triggering of the
mitochondrial-dependent pathway and caspase
3 activation. 
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